Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 685-690

  Fatkenheuer G ^a   Duvivier, C ^b   Rieger, A ^c   Durant, J ^d   Rey, D ^e   Schmidt, W ^f   Hill, A ^g   van Delft, Y ^h   Marks, S ^h   Vetter, N ⁱ   Greil, R ⁱ   Pedersen, C ⁱ   Storgaard, M ⁱ   Morlat, P ⁱ   Katlama, C ⁱ   Cotte, L ⁱ   Duvvier, C ⁱ   Esser, S ⁱ   Stellbrink, C ⁱ   Stoll, M ⁱ   Stephan, C ⁱ   Stoehr, A ⁱ   Rockstroh, J ⁱ   Banhegyi, D ⁱ   Itzchak, L ⁱ   Shahar, E ⁱ   Maayan, S ⁱ   Turner, D ⁱ   Lazzarin, A ⁱ   Antinori, A ⁱ   Carosi, G ⁱ   Minoli, L ⁱ   di Perri, G ⁱ   Filice, G ⁱ   Andreoni, M ⁱ   Duiculescu, D ⁱ   Rugina, S ⁱ   Erscoiu, S ⁱ   Streinu, A ⁱ   Pronin, A ⁱ   Pokrovsky, V ⁱ   Gruzdev, B ⁱ   Yakovlev, A ⁱ   Voronin, E ⁱ   Clotet, B ⁱ   Gatell, J ⁱ   Arribas, J ⁱ   Podzamczer, D ⁱ   Domingo, P ⁱ   Alvarez, C Miralles ⁱ   Quero, J Hernandez ⁱ   Furrer, H ⁱ   Feher, J ⁱ   Johnson, M ⁱ   Fox, J ⁱ   Nelson, M ⁱ   Fisher, M ⁱ   Orkin, C ⁱ   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c University Clinic   (Austria)

^d Hopital Archeti   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f Praxis   (Germany)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h Janssen   (Netherlands)

ⁱ NONE

Author keywords

Antiretroviral treatment; Cholesterol; Lipid elevations; Non nucleoside reverse transcriptase inhibitors; Nucleoside analogues

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CHOLESTEROL; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; HEART PALPITATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DOUBLE-BLIND METHOD; FEMALE; HIV; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PLACEBOS; PYRIDAZINES; VIRAL LOAD; YOUNG ADULT;

EID: 84863393499     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr533     Document Type: Article

References (28)

1. Thompson M, Aberg J, Cahn P et al. Antiretroviral treatment of adult HIV infection. 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
2. US Department for Health and Social Security. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents-January 10, 2011. http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7 (17 October 2011, date last accessed).
3. European AIDS Clinical Society. Guidelines for the Clinical Management of HIV Infected Adults in Europe. http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41 (17 October 2011, date last accessed).
4. Munoz-Moreno J, Fumaz C, Ferrer M et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates and management. A neurobehavioural review. AIDS Rev 2009; 11: 103-9.
5. Squires K, Lazzarin A, Gatell J et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9.
6. Hill A, Sawyer A, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 2009; 10: 1-12.
7. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States-April 29, 2009. http://www.emcureaidsinfo.com/pdf/PerinatalGL_2009.pdf (17 October 2011, date last accessed).
8. Law M, Friis-Moller N, El-Sadr W et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Medicine 2006; 7: 218-30.
9. Grundy S, Cleeman J, Merz N et al. Implications of recent clinical trials for the national cholesterol education programme adult treatment panel III guidelines. Circulation 2004; 110: 227-39.
10. DAIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 2004. http://rsc.tech-res.com/safetyandpharmacovigilance/(17 October 2011, date last accessed).
11. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63.
12. Pozniak A, Morales-Ramirez J, Katabira E et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomised trial. AIDS 2010; 24: 55-65.
13. Cohen C, Molina JM, Cahn P et al. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients. In: Abstracts of the Eighteenth IAS Conference, Vienna, Austria, 2010. Oral Abstract Late Breaker THLBB206.
14. Lennox J, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet 2009; 374: 796-806.
15. Sierra-Madero J, Di Perri G, Wood R et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010; 11: 125-32.
16. Sax P, Tierney C, Collier A et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204: 1191-201.
17. Lalezari J, DeJesus E, Osiyemi O et al. Pharmacokinetics of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults. In: Abstracts of the Ninth International Conference on HIV Treatment, Glasgow, Scotland, 2008. Abstract PO413.
18. Katlama C, Haubrich R, Lalezari R et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
19. Nelson M, Stellbrink H, Podzamczer D et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011; 25: 335-40.
20. Gazzard B, Duvivier C, Zagler C et al. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 2011; 25: 2249-58.
21. Podzamczer D, Andrade-Villanueva J, Clotet B et al. Lipid profiles for nevirapine versus atazanavir/ritonavir both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment naïve HIV-1-infected patients (the ARTEN study). HIV Med 2011; 12: 374-82.
22. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26.
23. DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
24. Anderson K, Odell P, Wilson P. Cardiovascular disease risk profiles. Am J Heart Assoc 1990; 124: 293-8.
25. Hense H. Observations, predictions and decisions: assessing cardiovascular risk assessment. Int J Epidemiol 2004; 33: 235-9.
26. Wilson P, D'Agostino R, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
27. Fitch K, Anderson E, Hubbard J et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 2006; 20: 1843-50.
28. Silverberg M, Leyden W, Hurley L et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150: 301-3.